Barclays PLC Acquires 104,310 Shares of Accuray Incorporated (NASDAQ:ARAY)

Barclays PLC grew its holdings in Accuray Incorporated (NASDAQ:ARAY) by 97.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 210,819 shares of the medical equipment provider’s stock after purchasing an additional 104,310 shares during the period. Barclays PLC owned about 0.21% of Accuray worth $380,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Renaissance Technologies LLC boosted its position in shares of Accuray by 0.3% during the second quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock valued at $5,118,000 after buying an additional 7,500 shares during the last quarter. Foundry Partners LLC grew its stake in shares of Accuray by 51.3% in the third quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock worth $3,937,000 after acquiring an additional 741,900 shares during the period. Geode Capital Management LLC raised its holdings in shares of Accuray by 2.1% during the third quarter. Geode Capital Management LLC now owns 2,179,396 shares of the medical equipment provider’s stock valued at $3,924,000 after purchasing an additional 45,548 shares during the last quarter. State Street Corp lifted its position in Accuray by 3.8% during the third quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider’s stock valued at $3,410,000 after purchasing an additional 70,008 shares during the period. Finally, FMR LLC boosted its holdings in Accuray by 27.2% in the third quarter. FMR LLC now owns 582,591 shares of the medical equipment provider’s stock worth $1,049,000 after purchasing an additional 124,459 shares during the last quarter. Hedge funds and other institutional investors own 64.08% of the company’s stock.

Accuray Price Performance

NASDAQ ARAY opened at $2.24 on Friday. The company has a 50-day moving average price of $1.99 and a 200-day moving average price of $1.93. Accuray Incorporated has a 52 week low of $1.40 and a 52 week high of $2.99. The company has a quick ratio of 0.87, a current ratio of 1.63 and a debt-to-equity ratio of 3.59. The firm has a market capitalization of $225.28 million, a P/E ratio of -13.18 and a beta of 1.47.

Accuray (NASDAQ:ARAY) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. The business had revenue of $101.55 million for the quarter, compared to the consensus estimate of $98.10 million. During the same period last year, the firm earned ($0.03) earnings per share. Equities research analysts anticipate that Accuray Incorporated will post 0.01 earnings per share for the current year.

Analyst Ratings Changes

Separately, StockNews.com cut Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.